<DOC>
	<DOC>NCT01546909</DOC>
	<brief_summary>PRIMARY OBJECTIVES - To describe in 11 to 13-year-old children previously vaccinated with either REVAXIS or DT Polio at 6 years of age the antibody persistence against diphtheria, tetanus, and poliovirus types 1, 2 and 3 - To describe one month after a booster dose of TETRAVAC-ACELLULAIRE the immune responses against diphtheria, tetanus, and poliovirus types 1, 2 and 3 SECONDARY OBJECTIVES - To describe other parameters of the antibody persistence against diphtheria, tetanus and poliomyelitis antigens - To describe other parameters of the immune responses to diphtheria, tetanus and poliomyelitis antigens one month after a booster dose of TETRAVAC-ACELLULAIRE - To describe the safety profile of a booster dose of TETRAVAC-ACELLULAIRE</brief_summary>
	<brief_title>Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE</brief_title>
	<detailed_description />
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Healthy child 11 to 13 years of age previously vaccinated in Study F05TdI301 Immunization against diphtheria, tetanus, pertussis and/or poliomyelitis beyond Study F05TdI301 Previous clinical or bacteriological diagnosis of diphtheria, tetanus, pertussis or poliomyelitis Known or suspected immune dysfunction Receipt of medications / vaccination that may interfere with study assessments Known true hypersensitivity to any of the vaccine components or to a vaccine containing the same substances Known personal history of encephalopathy, seizure disorder or progressive, evolving or unstable neurological condition Thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection Any medical condition that might interfere with the evaluation of the study objectives Febrile illness</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>